Economic analysis comparing induction of labor and expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks (PPROMEXIL trial)

Acta Obstet Gynecol Scand. 2014 Apr;93(4):374-81. doi: 10.1111/aogs.12329. Epub 2014 Jan 29.

Abstract

Objective: To compare the costs of induction of labor and expectant management in women with preterm prelabor rupture of membranes (PPROM).

Design: Economic analysis based on a randomized clinical trial.

Setting: Obstetric departments of eight academic and 52 non-academic hospitals in the Netherlands.

Population: Women with PPROM near term who were not in labor 24 h after PPROM.

Methods: A cost-minimization analysis was done from a health care provider perspective, using a bottom-up approach to estimate resource utilization, valued with unit-costs reflecting actual costs.

Main outcome measures: Primary health outcome was the incidence of neonatal sepsis. Direct medical costs were estimated from start of randomization to hospital discharge of mother and child.

Results: Induction of labor did not significantly reduce the probability of neonatal sepsis [2.6% vs. 4.1%, relative risk 0.64 (95% confidence interval 0.25-1.6)]. Mean costs per woman were €8094 for induction and €7340 for expectant management (difference €754; 95% confidence interval -335 to 1802). This difference predominantly originated in the postpartum period, where the mean costs were €5669 for induction vs. €4801 for expectant management. Delivery costs were higher in women allocated to induction than in women allocated to expectant management (€1777 vs. €1153 per woman). Antepartum costs in the expectant management group were higher because of longer antepartum maternal stays in hospital.

Conclusions: In women with pregnancies complicated by PPROM near term, induction of labor does not reduce neonatal sepsis, whereas costs associated with this strategy are probably higher.

Keywords: Costs; PPROM; expectant management; induction; labor.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics / administration & dosage
  • Analgesics / economics
  • Cost Control
  • Cost Savings
  • Cost-Benefit Analysis
  • Critical Care / economics
  • Delivery, Obstetric / economics
  • Female
  • Fetal Membranes, Premature Rupture / economics*
  • Fetal Membranes, Premature Rupture / therapy*
  • Humans
  • Incidence
  • Infant, Newborn
  • Intensive Care, Neonatal / economics
  • Labor, Induced / economics*
  • Labor, Induced / methods
  • Length of Stay / economics
  • Monitoring, Physiologic / economics
  • Netherlands / epidemiology
  • Pregnancy
  • Pregnancy Trimester, Third
  • Sepsis / epidemiology
  • Watchful Waiting / economics*

Substances

  • Analgesics

Associated data

  • ISRCTN/ISRCTN29313500